Explore how project management information systems guide each project phase, the tools that support them, and real-world use across industries. Project management information systems extend far beyond ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock rose 3.1% on Tuesday after the company announced it has completed its first commercial shipments of YARTEMLEA (narsoplimab-wuug) to distributors ...

Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant ...

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — Omeros Corporation (NASDAQ: OMER) today ...

What if you could transform hours of tedious spreadsheet work into just minutes of streamlined efficiency? Simon Sez IT takes a closer look at how Excel’s most powerful functions can transform the way ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of hematopoietic ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock surged 61.6% Wednesday after the FDA approved YARTEMLEA, the first and only treatment for hematopoietic stem cell transplant-associated ...

(RTTNews) - Omeros Corporation (OMER) today announced that the FDA has approved YARTEMLEA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...